Micro Solutions Life ScienceRU

Micro Solutions / Life Science

SOLIDaccuTest DNA (84 genes) and RNA (29 genes)

NGS panel of solid tumors: 84 DNA genes and 29 RNA genes for selecting targeted therapy

Product overview

NGS panel of solid tumors: 84 DNA genes and 29 RNA genes for selecting targeted therapy

for lung, stomach, colon, breast and ovarian cancer

SOLIDaccuTest combines a DNA panel of 84 genes and an RNA panel of 29 genes for the NGS diagnosis of solid tumors and the selection of targeted therapy.

The next-generation sequencing panels include 84 genes in the DNA panel and 29 genes in the RNA panel, which are important in lung, stomach, colon, breast and ovarian cancer. The RNA panel further detects fused transcripts. The test results are formed in 3 to 3.5 days and used to select targeted therapies.

The SOLIDaccuTest DNA and RNA panels cover genes clinically relevant to solid tumors; the duration of the analysis is 3-3.5 days.

Key figures

84

DNA-panel

29

smelter

3–3.5 days

time-frame

Applications

Models and configurations

Panel coverage

Clinical challenge

Time limit for implementation

DNA panel

Genes84 (cancer of the lung, stomach, colon, breast, ovaries)

RNA panel

Genes29 (merged transcripts)

Time limit for implementation

Time frame for analysis3–3.5 days

Related equipment types

Related products

Classification

Documents

Manufacturer sources